Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial

[1]  Yoon-Koo Kang,et al.  Randomized phase III trial of sorafenib versus placebo in patients with advanced hepatocellular carcinoma (HCC) , 2007 .

[2]  T. de Baère,et al.  Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) , 2007, Cancer.

[3]  D. Amadori,et al.  Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Young-Ae Park,et al.  A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer , 2006, British Journal of Cancer.

[5]  S. Oh,et al.  Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma , 2006, Cancer Chemotherapy and Pharmacology.

[6]  S. Park,et al.  Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma , 2006, BMC Cancer.

[7]  W. Lau,et al.  A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. , 2005, Journal of the National Cancer Institute.

[8]  P. Philip,et al.  Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Manal M. Hassan,et al.  Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma , 2004, Cancer.

[10]  A. Burroughs,et al.  Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. , 2004, The Lancet. Oncology.

[11]  T. Conroy,et al.  XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Ö. Özyılkan,et al.  Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon‐alpha, doxorubicin and 5‐fluorouracil chemotherapy , 2002, Cancer.

[13]  R. Stupp,et al.  Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Van Cutsem,et al.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[16]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[18]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[19]  B. Reigner,et al.  Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients , 2000, Cancer Chemotherapy and Pharmacology.

[20]  B. Reigner,et al.  Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  F. Izzo,et al.  A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients , 1998, Hepatology.

[22]  H. Ishitsuka,et al.  Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.

[23]  M. Al-Ahwal,et al.  Chemoembolization in hepatocellular carcinoma. , 1998, Saudi medical journal.

[24]  David Machin,et al.  Sample Size Tables for Clinical Studies , 1997 .

[25]  S. Okada.  [Chemotherapy of hepatocellular carcinoma]. , 1998, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[26]  克也 平山,et al.  A prospective randomized trial , 1995 .

[27]  F. Lévi,et al.  Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. , 1990, Journal of the National Cancer Institute.

[28]  Ching-lung Lai,et al.  Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial , 1988, Cancer.

[29]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.